“…Recent bioinformatics and high throughput experimental screening approaches lead to the identification of candidate CR/DR mimetics in C. elegans that now require investigation in higher organisms (Calvert et al, 2016; Lucanic et al, 2016). Additional compounds that recently were shown to increase wildtype C. elegans lifespan in candidate testing or small scale screening approaches include small molecules and metabolites such as dimethyl sulfide (Guan et al, 2017), α-ketoacids (Mishur et al, 2016), fructose (Zheng et al, 2017), the d-fructose epimer d-allulose (Shintani et al, 2017), the ω−3 polyunsaturated fatty acid alpha-linolenic acid (ALA) and ALA-derived oxylipin-metabolites (Qi et al, 2017), the proteasome activator 18α-Glycyrrhetinic Acid, a triterpenoid from licorice (Papaevgeniou et al, 2016) and FDA-approved drugs such as rifampicin for tuberculosis (Golegaonkar et al, 2015) and the angiotensin-converting enzyme inhibitor captopril (Kumar et al, 2016) and hydralazine, which are both used to treat hypertension (Dehghan et al, 2017). Many of these compounds apparently act, at least in part, by activating or stabilizing lifespan-regulatory key transcription factors (Table 1), such as daf-16 (18α-Glycyrrhetinic Acid, rifampicin, captopril), hlh-30 (selective inhibitors of nuclear export), hif-1 (α-ketoacids), nhr-49 (ALA) and skn-1 (ALA-metabolites, 18 α-Glycyrrhetinic, hydralazine).…”